Regulatory & NPN

How to Get an NPN in Canada: Requirements, Timelines and Costs

How to Get an NPN in Canada: Requirements, Timelines and Costs

How to Get an NPN in Canada: Requirements, Timelines and Costs

Sources checked 15 November 2026

A practical guide to NPN application classes, review timelines, project costs and the documents needed to prepare your Canadian supplement launch.

A practical guide to NPN application classes, review timelines, project costs and the documents needed to prepare your Canadian supplement launch.

The short answer

To get an NPN, confirm your product belongs in the natural health product category, establish its formula and proposed claims, prepare the appropriate application and obtain a product licence from Health Canada before sale. Published decision targets are 60, 90 and 210 calendar days for Classes I, II and III. Preparation, testing and commercial readiness are separate parts of your launch plan.

  1. Confirm the Canadian product category and application eligibility.

  2. Finalize ingredient forms, amounts and the proposed daily dose.

  3. Check the proposed claims against monographs or supporting evidence.

  4. Determine whether the complete application fits Class I, II or III.

  5. Prepare the application and reconcile the label with it before filing.

  6. Answer information requests and complete launch requirements. Plan site licensing and importing in parallel.

Who this article is for

Founders preparing a first Canadian launch, product developers scoping a new SKU, regulatory and quality managers assembling a submission, and US or international brands adding Canada to their roadmap.

Key takeaways

  • Published service standards: Class I 60, Class II 90 and Class III 210 calendar days. These are not guaranteed approval dates or current average waiting times.

  • Build preparation and commercial readiness into the schedule separately.

  • Proposed government fees remain deferred; consulting and testing are separate costs.

  • Check product licensing, Canadian site licensing and import arrangements together.

Prepared by Kompete Consulting. Sources checked 15 November 2026 against Health Canada’s application policy and bulletins on eligibility, review order, finished product specifications, cost recovery and foreign-site requirements. See the official references below.

Plain supplement bottle on a neutral beige background.

Plan the formula, claims and licensing pathway together before committing to production. Illustrative stock photograph.


What is an NPN, and when do you need one?


A Natural Product Number is the eight-digit identifier issued with a Canadian natural health product licence. It identifies the authorised product and its conditions of use. It is not a blanket approval for a brand, a factory or every claim a marketing team might want to make. Homeopathic medicines use a DIN-HM instead.


Start with classification. A capsule, powder or gummy does not qualify for an NPN simply because it contains familiar supplement ingredients. Composition, intended use and presentation matter. Foods and supplemented foods follow different pathways. For a product that belongs in the NHP category, licensing must be completed before sale in Canada.


Before you apply: confirm the 12-month eligibility requirement

Health Canada accepts Class I, II and III applications for products intended to be sold or manufactured in Canada within 12 months of receiving authorization. The current web PLA includes the eligibility questions: at least one qualifying answer must be yes before the form can be finalized. Confirm your actual Canadian sale or manufacturing plan before filing; this is not a requirement to already be selling when you apply.

Which NPN application class applies?


Health Canada groups applications by how they use its monographs: pre-assessed ingredient or product information covering conditions such as dose, claims and risk statements. These are simplified planning descriptions; the complete formula and proposed label determine the route.


Class I: exact match to one monograph


The application fully matches one monograph, including its permitted parameters and wording. A multi-ingredient product can qualify where a single applicable monograph covers it; Class I does not simply mean one ingredient. Published service standard: 60 calendar days.


Class II: eligible monograph combinations or limited deviations


The application is fully supported by qualifying monographs, including acceptable combinations or minor wording deviations that preserve the original meaning. Ingredient compatibility and combined conditions of use still need assessment. Published service standard: 90 calendar days.


Class III: assessment beyond Classes I and II


This route requires a fuller safety, efficacy and/or quality assessment. Examples include unsupported conditions of use or certain formulations designed to alter absorption. Published service standard: 210 calendar days. Familiar ingredients alone do not establish eligibility for a simpler class.


How long does it take to get an NPN?


Timeline check: 15 November 2026. Health Canada lists service standards of 60, 90 and 210 calendar days for Classes I, II and III respectively. These include administrative screening and regulatory screening/assessment. They concern a regulatory decision, which may be a licence or refusal, not guaranteed approval or measured current waiting times. Class III applications requiring joint assessment with another Health Canada directorate are outside the 210-day standard.

Queue guidance is separate from the service standard

Health Canada’s 11 March 2026 bulletin reported that prioritized applications awaiting review exceeded review capacity. For applications received before 15 December 2025, review order is based on the Workload Management Form submission date, with the original receipt date breaking ties. For applications received on or after 15 December 2025, the receipt date determines priority. This is dated queue guidance, not a live waiting-time estimate.

The official sources reviewed do not provide a current average turnaround for each application class. A fixed waiting-time estimate would therefore be misleading. Plan around the specific application, outstanding information and commercial dependencies, and revisit official updates before confirming a launch date.


A realistic launch schedule has three separate parts. Preparation comes first: resolving formula details, selecting claims, gathering supporting records and completing the application. Regulatory review follows submission. Commercial readiness includes production, testing, final artwork and importer arrangements. Some activities can run together, but a review target is not a complete concept-to-sale timeline.


Preparation has no single reliable duration for every product. A complete supplier package and settled monograph-aligned claims create a different workload from an unfinished blend or a new evidence package. At project scoping, identify what is ready, what is missing, who owns each task and which items prevent filing. Use that assessment to set the submission date rather than working backwards from a launch promise.


What does an NPN application cost?


Separate the regulator’s charges from the work needed to prepare and launch your product. As checked on 15 November 2026, the proposed NHP cost-recovery fees have not been implemented. Health Canada says it will revisit the proposal after program adjustments. Proposed fee tables should not be presented as current application charges.


Regulatory preparation and consulting


This covers work such as classification, formula and monograph review, evidence assessment, application preparation, label reconciliation and responses to review questions. The scope changes with the application class, the quality of the starting documents and the number of products. Ask whether a quote includes response rounds, artwork review and post-licensing support.


Testing, technical documents and packaging


Laboratory work, stability support, translation, artwork and manufacturer documentation are separate budget lines unless expressly included. A low filing quote may exclude those activities. Distinguish the cost of preparing the submission from the cost of getting a sale-ready product into inventory.


For a useful Kompete project estimate, send the product format, formula, proposed daily dose, intended claims, manufacturing country and target launch date. We can scope the work against the actual product instead of attaching an unsupported flat price to every NPN application.


Need an estimate for your product? Explore our Class I, II and III NPN application support.


How to prepare an NPN application: the practical sequence


1. Establish the Canadian product category


Resolve whether the proposed product belongs in the NHP framework before committing to a label format. If the concept sits near the food boundary, assess its whole presentation, not just its ingredient list. This is especially important for drink mixes and products promoted as everyday foods.


2. Build a controlled formula record


Record each medicinal ingredient’s identity, source, form, quantity per dosage unit and relevant potency. Include non-medicinal ingredients and their functions. For botanicals, obtain details such as plant part and extract information; for minerals, distinguish the compound weight from the elemental contribution. Assign a version and owner so the manufacturer and application team work from the same record.


3. Match the evidence to the proposed use


Write the intended claims, target population, dose, directions and duration together. Evaluate the proposed combination rather than assuming that separate ingredient precedents establish the finished product’s suitability. If the desired positioning changes the evidence route, make that commercial decision before final artwork.


4. Determine the application class

Assess the whole product against the current Class I, II and III criteria. Record where the formula and proposed use meet the relevant monograph conditions, and where additional evidence or assessment is needed. Choose the class from that assessment, rather than from the ingredient names alone.

5. Prepare and reconcile the submission


Complete the applicable application and supporting documentation, with company details and ingredient terminology consistent across records. Compare the proposed label with the application line by line. Resolve discrepancies in ingredient quantities, dosage units, risk statements and recommended use before filing.


6. Manage questions and prepare for launch


Keep the submitted version, correspondence and supporting documents together. If Health Canada requests information, assign an owner to each question and respond within the stated deadline. Review proposed changes across the entire file so that correcting one answer does not create a contradiction elsewhere.


Specifications and testing: what changed in June 2026?


From June 15, 2026, finished product specifications no longer need to accompany Class II and III product licence and amendment applications at filing. This changes the submission process, not the underlying responsibility to maintain appropriate specifications. Health Canada can still request them.


Keep the quality work moving alongside the regulatory work. Agree the identity, potency and relevant contaminant tests, acceptance criteria, testing responsibilities and shelf-life support with your manufacturer. A document being absent from the initial submission package does not make it unnecessary for your product’s quality system.


Laboratory scientist using a pipette with sample tubes.


Quality planning runs alongside licensing: define specifications, testing responsibilities and the evidence supporting the finished product. Illustrative stock photograph.


Product licence, site licence and Canadian importer: who does what?


The product licence authorises the specific NHP. Site licensing covers regulated activities at Canadian sites, including manufacturing, packaging, labelling and importing. An NPN does not replace those obligations.


For an overseas-made product, identify the appropriately licensed Canadian importer and arrange the required foreign-site GMP evidence and listing on the importer’s site licence. A foreign manufacturer does not simply obtain the same Canadian site licence as a domestic operator. Allocate responsibility for records, release and changes in the supply agreement.


Foreign sites and warehouses: the February 2026 change

Health Canada ended the Foreign Site Reference Number (FSRN) process on 16 February 2026. Importers should address foreign-site GMP evidence through the Canadian site-licensing process, rather than plan around a new or renewed FSRN. Foreign warehouses no longer need to be listed on the importer’s site licence, but they must still meet applicable GMP requirements. Confirm the evidence and responsibilities with the importer early.

Common reasons NPN applications are delayed or refused


The most useful readiness review looks for contradictions and missing decisions. Examples include a supplier changing an ingredient form without updating the formula, the label showing a daily serving while the application describes one capsule, or a marketing claim being strengthened after the evidence review.


Another frequent planning trap is treating regulatory, manufacturing and packaging work as separate projects. Put them on one change log. A change to dose can affect the claim, capsule count, label space and production quote at the same time. An agreed approval process helps prevent each team from solving a different version of the product.


Issue

Possible consequence

How to prevent it

Wrong application class

Screening issues or a different assessment pathway.

Check the complete formula, claims and monograph fit before selecting the class.

Incomplete eligibility answers

The application cannot be finalized without the required qualifying answer.

Confirm the genuine intent to sell or manufacture in Canada within 12 months of authorization; answer the current PLA questions accurately.

Label and application disagree

Clarification requests or revisions.

Reconcile ingredient amounts, daily dose, claims and risk statements against one controlled product record.

Evidence does not match the product

Unresolved safety or efficacy concerns may lead to refusal.

Match the evidence to ingredient form, dose, population and proposed use; explain relevant differences.

Missed information-request deadline

The application may be refused.

Assign an owner to incoming requests, track each stated deadline and submit a complete response.

Illustrative example: the claim changes the project


A brand has a capsule formula and a packaging concept promising a specific sleep benefit. Before quoting the filing, the team checks whether the proposed ingredients, doses and claim fit the available evidence pathway. It can revise the positioning, adjust the formulation, or evaluate a broader evidence submission. None is automatically the right option. The decision should reflect the brand’s intended benefit, evidence strength and launch constraints before packaging is printed.


What happens after your NPN is issued?


Reconcile the final licence with the commercial formula, bilingual artwork, directions and risk information. Confirm site and importer readiness and the quality documentation needed for release. Treat subsequent changes as regulatory decisions: depending on their nature, they may require a notification, amendment or new application. Do not assume every reformulation can be handled as a simple label update.


Get a product-specific NPN plan


Planning an NPN application? Tell us your product format, intended claims and project stage. We’ll identify the information needed to scope the next steps.


Request an NPN project scope


What to prepare

  • Product format, target population and intended Canadian use.

  • Controlled formula with medicinal ingredients, forms, sources, potency and amounts per dosage unit.

  • Non-medicinal ingredients, sub-ingredients and their purposes.

  • Proposed daily dose, claims, directions and applicable risk information.

  • Supplier records and a documented monograph or evidence assessment.

  • Specifications, test plan, responsibilities and shelf-life support.

  • Proposed English and French label copy matched to the application.

  • Canadian manufacturing or licensed importer arrangements and foreign-site evidence where relevant.

  • Target launch date, unresolved decisions and named document owners.

  • Confirmed intent to sell or manufacture in Canada within 12 months of authorization, with accurate PLA eligibility answers.

Frequently asked

How long does NPN approval take?

As verified on 15 November 2026, published service standards are 60 calendar days for Class I, 90 for Class II and 210 for Class III, including screening and assessment. They are decision standards, not approval guarantees or measured current waiting times. Review-order guidance, information requests and the particular file must also be considered. Preparation and commercial readiness are separate.

How much does an NPN application cost?

The proposed government NHP cost-recovery fees remain unimplemented as last checked on 15 November 2026. Consulting, evidence preparation, testing, translation and artwork can still create project costs. Kompete scopes those against your product and documents rather than quoting an invented universal fee.

Can I sell while the application is being reviewed?

An application in progress is not market authorisation. A product classified as an NHP needs its licence before sale in Canada, with compliant labelling and the applicable site and import arrangements.

Does every NPN application need a new clinical trial?

No. The evidence needed depends on the product and proposed conditions of use. Monographs can support qualifying applications. An application outside those parameters needs an evidence assessment; that does not automatically mean commissioning a new clinical trial.

Can a multi-ingredient formula be Class I?

Potentially, where one applicable multi-ingredient monograph covers the product and all Class I criteria are satisfied. The number of ingredients alone does not determine the application class.

Do I need to submit finished product specifications?

Since June 15, 2026, FPS no longer need to accompany Class II and III applications and amendments at filing. Appropriate specifications must still be maintained, and Health Canada can request them.

Does a US supplement label or FDA status replace an NPN?

No. Canadian classification, licensing and labelling must be assessed separately. For an imported NHP, the Canadian importer also needs the appropriate site licence and foreign-site arrangements.

What should I send Kompete to get started?

Send your product format, complete formula if available, proposed daily dose, intended claims, current label, manufacturing country and target launch date. If the formula is still a concept, say which decisions remain open so the initial scope can address them.

Next step

Planning an NPN application?

Planning an NPN application?

Planning an NPN application?

Tell us your product format, intended claims and project stage. We’ll identify the information needed to scope the next steps.

Request an NPN project scope